Jonathan Visentin is Assistant Professor at the University of Bordeaux and Hospital Practitioner at the Bordeaux University Hospital. Laureate of the prestigious Marie Sklodowska-Curie individual fellowship in 2020, he spent two years in the United States. Now back at the University of Bordeaux, he’s talking about the benefits of this experience and encouraging researchers to apply. Check out his interview bellow…
Articles
Maël Lemoine obtains ANR project
He will be leading the project MEASURAGE, a project on the theoretical framework necessary to correctly measure the progression of aging. Partners are Adrien Barton (Université de Toulouse) and Alan Cohen (Columbia University).
About the project:
The question of measuring the progression of aging has become crucial. Some think that it might be a predictor of health-related outcomes, others, that it would help determine if some drugs really are geroprotective, i.e., slow down the progression of aging. There is an intuitive idea that biological aging can be measured more accurately than with the progression of time, but this raises conceptual difficulties and the need for a concerted strategy. Is it possible to measure the progression of one and the same process across tissues? If not, how is it that we can frame such a project?
One PhD and one postdoc will be hired by October 2024.
Congrats to Johan Garaude for the ANR award
Together with Judith Favier in Paris Johan Garaude was awarded a grant from the ANR PRCE program for their project SuccINNATE, which aims at studying the emergent role of Succinate Dehydrogenase in the control of inflammatory innate immune responses.
Claire Leibler was awarded an ANR JCJC Grant
Congratulation Claire for obtaining this grant from the ANR to work on differences between TLR7 and TLR9 signalling in B cells and their impact on lupus pathogenesis.
Congratulations to Katia Boniface and Julien Seneschal’s group
The “Crosstalk between immune and epidermal cells” group lead by Katia Boniface and Julien Seneschal was awarded a grant by the “Société Française de Dermatologie” (SFD) to work on the characterization of resident memory T cells in non lesional skin of vitiligo.
Their PhD student, Ribal Merhi, was also awarded a grant by the SFD to continue his work on the role of type I Interferons in vitiligo.
Congrats!
Congratulations to Laure Migayron!
Congratulations to Laure Migayron who got awarded a grant by the “Société de Recherche Dermatologique” to work on the charaterization of T cells in vitiligo. Well done and best of luck!
ImmunoConcEpT’s fresque du climat
We had our first “la Fresque du Climat” at ImmunoConcEpT which was animated by a colleague from the MFP lab. Many thanks to her!
It was a great time during which we learnt a lot of things about climate change and we talked about solutions which we can apply in our professional and personal life.
Other ones will come very soon!
![](https://immunoconcept.cnrs.fr/wp-content/uploads/2023/05/2023-05-15-Fresque-climat1.jpeg)
Conference on DC and Macrophages in Bordeaux organised by the French DC society including Johan Garaude and Vanja Sisirak
Title: Development, metabolism and function of dendritic cells and macrophages in health and disease
Dates: 7th to 8th December 2023
Where: Université de Bordeaux Pey Berland
Registration will start in May 2023
Confirmed Speakers
Ido Amit, Weizmann Institute of Science, Rehovot, Israel
Raphael Arguelo, Centre d’Immunologie de Marseille-Luminy, France,
Camille Bigenwald, Institut Gustave Roussy, Paris, France
Matthew Collin, Newcastle University, UK
Charles-Antoine Dutertre, Institut Gustave Roussy, Paris, France
Ruth Franklin, Harvard Stem Cell Institute, Boston, USA
Bart Lambrecht, VIB – Ghent University, Belgium
Ana-Maria Lennon, Institut Curie, Paris, France
Sophia Maschalidi, VIB – Ghent University, Belgium
Massimiliano Mazzone, VIB – Ghent University, Belgium
Evanna Mills, Dana Farber Cancer Institute, Boston, USA
Shalin Naik, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
Giulia Pasqual, University of Padova, Italy
Caetano Reis e Sousa, CRICK institute, London, UK
Maya Saleh, Immunoconcept, University of Bordeaux, France
Stefani Spranger, MIT Department of Biology, Boston, USA
The group of Patrick Blanco was awarded a grant by the FRM
The team of Dr. Blanco has been awarded a grant from the Fondation pour la Recherche Medicale to work on the on a tumor-derived peptide function in the prevention of autoimmune diseases. Excited to start this new project…
The group of Dr. Julien Seneschal published a NEJM, congrats
Background: Lebrikizumab, a high-affinity IgG4 monoclonal antibody targeting interleukin-13, prevents the formation of the interleukin-4Rα-interleukin-13Rα1 heterodimer receptor signaling complex.
Methods: We conducted two identically designed, 52-week, randomized, double-blind, placebo-controlled, phase 3 trials; both trials included a 16-week induction period and a 36-week maintenance period. Eligible patients with moderate-to-severe atopic dermatitis (adults [≥18 years of age] and adolescents [12 to <18 years of age, weighing ≥40 kg]) were randomly assigned in a 2:1 ratio to receive either lebrikizumab at a dose of 250 mg (loading dose of 500 mg at baseline and week 2) or placebo, administered subcutaneously every 2 weeks. Outcomes for the induction period were assessed up to 16 weeks and are included in this report. The primary outcome was an Investigator’s Global Assessment (IGA) score of 0 or 1 (indicating clear or almost clear skin; range, 0 to 4 [severe disease]) with a reduction (indicating improvement) of at least 2 points from baseline at week 16. Secondary outcomes included a 75% improvement in the Eczema Area and Severity Index score (EASI-75 response) and assessments of itch and of itch interference with sleep. Safety was also assessed.
Results: In trial 1, the primary outcome was met in 43.1% of 283 patients in the lebrikizumab group and in 12.7% of 141 patients in the placebo group (P<0.001); an EASI-75 response occurred in 58.8% and 16.2%, respectively (P<0.001). In trial 2, the primary outcome was met in 33.2% of 281 patients in the lebrikizumab group and in 10.8% of 146 patients in the placebo group (P<0.001); an EASI-75 response occurred in 52.1% and 18.1%, respectively (P<0.001). Measures of itch and itch interference with sleep indicated improvement with lebrikizumab therapy. The incidence of conjunctivitis was higher among patients who received lebrikizumab than among those who received placebo. Most adverse events during the induction period were mild or moderate in severity and did not lead to trial discontinuation.
Conclusions: In the induction period of two phase 3 trials, 16 weeks of treatment with lebrikizumab was effective in adolescents and adults with moderate-to-severe atopic dermatitis. (Funded by Dermira; ADvocate1 and ADvocate2 ClinicalTrials.gov numbers, NCT04146363 and NCT04178967, respectively.).